Present appointment: Scientific Advisor
Phone: +36 1 210 29 30/Ext. 56393
Email: 
, lharsing@t-email.hu
Education and qualification:
- 1966-1972, Semmelweis University, Faculty of Medicine, Budapest
Present affiliation:
- 2009- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest
Previous affiliations, Hungary:
- 1973-1981 Assistant Professor, Department of Pharmacology, Semmelweis University
- 1981-1986 Senior Research Fellow, Institute of Experimental Medicine, Hungarian Academy of Sciences
- 1986-1995 Associate Professor Department of Pharmacology, Postgraduate School of Medicine, Budapest
- 1992-2000 Vice Director, Institute for Drug Research, Budapest
- 2000-2008 Vice Director, EGIS Pharmaceuticals Plc, Budapest
Previous affiliations, USA:
- 1980-1981 National Institute of Mental Health, Washington, DC
- 1985-1986 Montefiore Hospital, Albert Einstein Colloge of Medicine, New York, NY
- 1989-1992 Center for Neurochemistry, New York University, Orangeburg, NY
- 1995-1996 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA
Educational activities:
- Lecturing in pharmacology at universities and in postgraduate and PhD schools, graduate and postgraduate levels in Hungarian and English
Scientific Qualifications:
- 1984, PhD, Regulation of Cholinergic Neurotransmission in the Striatum
- 1992, DSc, Heterogeneity of Alpha-2 Adrenoceptors
- 1994, Lecturer in Pharmacology (Dr. Med. Habil.)
Merits and Awards:
- Fogarty International Fellowship, National Institutes of Health, 1980,1995
- Issekutz Memorial Medal, Hungarian Pharmacological Society, 2000
- Order of Merit of Hungary 2018
Research areas:
- experimental pharmacology, academic and industrial
- neuropsychopharmacology, neurotransmitter release, neurochemistry
Scientific publications and Scientometric data:
- scientific publications: 272
Chapters in textbooks: 39
Abstracts in journals and proceedings: 60
Patents in pharmaceutical drug development: 42
Cumulative impact factor: 259,869
Number of citations: independent 2436, total 3237
Hirsh index: 33
Drug development in preclinical phases:
- azidoethylmorphine, antitussive drug
- SCT-66, α2 adrenoceptor antagonist, antidepressant drug, US 4,851,416
- GYKI-46903, non-competitive 5-HT3 receptor antagonist
- EGIS-14111, glycine transporter-1 inhibitor
- (-)BPAP, catecholaminergic activity enhancer drug
Drug development in clinical phase:
- EGIS-11150/S36549, atypical antipsychotic, schizophrenia, US 20050043314 A1, Phase I clinical trial
- GYKI-16084, postsynaptic α1 and α2 adrenoceptor antagonist, benign prostate hyperplasia, US 619441 B1, Phase II clinical trial
- EGIS-13529/S44819, α5 GABAA receptor inverse agonist, post-stroke recovery, US 20120232065 A1, Completed phase II clinical trial
Editorial activities in periodicals:
- Neurochemical Research, Associate Editor
- Neurochemistry International, Current Medicinal Chemistry, memberships in editorial boards
Membership in professional societies:
- Hungarian Pharmacological Society
- Hungarian Physiological Society
- Society for Neuroscience, USA
- European Society for Neuroscience
- Australian Neuroscience Society
- Society of Neuroscience in Africa (SONA)
- International Society for Neurochemistry